Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

Article  PubMed  Google Scholar 

Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG. 2005;112:857–65.

Article  PubMed  Google Scholar 

Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe SC, von Gruenigen VE, Bruner DW, Reeve BB, Wenzel L. Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst 2014, 106.

Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Dugalic MG, Sengul D, Detanac DA, Sengul I, Detanac D, et al. Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian oncology centre. Clin (Sao Paulo). 2023;78:100204.

Article  Google Scholar 

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: ovarian cancer. [https://www.seer.cancer.gov/statfacts/html/ovary.html]

Kobel M, Kang EY. The evolution of ovarian carcinoma subclassification. Cancers (Basel) 2022, 14.

Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35:151–6.

Article  PubMed  Google Scholar 

Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021;1875:188503.

Article  CAS  PubMed  Google Scholar 

Hellstrom I, Yip YY, Darvas M, Swisher E, Hellstrom KE. Ovarian carcinomas express HE4 epitopes independently of each other. Cancer Treat Res Commun. 2019;21:100152.

Article  PubMed  Google Scholar 

Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian Cancer. Int J Mol Sci 2022, 23.

Nebgen DR, Lu KH, Bast RC Jr. Novel approaches to ovarian Cancer screening. Curr Oncol Rep. 2019;21:75.

Article  PubMed  PubMed Central  Google Scholar 

Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009;9:555–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol. 2013;128:239–44.

Article  CAS  PubMed  Google Scholar 

Kim J, Beidler P, Wang H, Li C, Quassab A, Coles C, Drescher C, Carter D, Lieber A. Desmoglein-2 as a prognostic and biomarker in ovarian cancer. Cancer Biol Ther. 2020;21:1154–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–56.

Article  PubMed  PubMed Central  Google Scholar 

Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih Ie M, Kurman R, Dao F, Levine DA, Giuntoli R, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5:167ra164.

Article  Google Scholar 

Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjaer SK, Hruban RH, Shih IM et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med 2018, 10.

Gong G, Lin T, Yuan Y. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer. J Ovarian Res. 2020;13:30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szigeti KA, Galamb O, Kalmar A, Bartak BK, Nagy ZB, Markus E, Igaz P, Tulassay Z, Molnar B. [Role and alterations of DNA methylation during the aging and cancer]. Orv Hetil. 2018;159:3–15.

Article  PubMed  Google Scholar 

Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38:23–38.

Article  CAS  PubMed  Google Scholar 

Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95:11891–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358:1118–28.

Article  CAS  PubMed  Google Scholar 

Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54:414–23.

Article  CAS  PubMed  Google Scholar 

Muller D, Gyorffy B. DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188722.

Article  CAS  PubMed  Google Scholar 

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–97.

Article  CAS  PubMed  Google Scholar 

Wu Q, Lothe RA, Ahlquist T, Silins I, Trope CG, Micci F, Nesland JM, Suo Z, Lind GE. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 2007;6:45.

Article  PubMed  PubMed Central  Google Scholar 

Chmelarova M, Krepinska E, Spacek J, Laco J, Beranek M, Palicka V. Methylation in the p53 promoter in epithelial ovarian cancer. Clin Transl Oncol. 2013;15:160–3.

Article  CAS  PubMed  Google Scholar 

Fu M, Deng F, Chen J, Fu L, Lei J, Xu T, Chen Y, Zhou J, Gao Q, Ding H. Current data and future perspectives on DNA methylation in ovarian cancer (Review). Int J Oncol 2024, 64.

Jung Y, Hur S, Liu J, Lee S, Kang BS, Kim M, Choi YJ. Peripheral blood BRCA1 methylation profiling to predict Familial ovarian cancer. J Gynecol Oncol. 2021;32:e23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011;120:113–20.

Article  CAS  PubMed  Google Scholar 

Zhao X, Yang M, Fan J, Wang M, Wang Y, Qin N, Zhu M, Jiang Y, Gorlova OY, Gorlov IP, et al. Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls. Cancer. 2024;130:913–26.

Article  CAS  PubMed  Google Scholar 

Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, Kristiansen M, Leavy OC, Manchanda R, Bjorge L, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nat Commun. 2022;13:448.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, Irizarry RA. Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. Bioinformatics. 2014;30:1363–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ChAMP. The Chip Analysis Methylation Pipeline. NBeads filter criteria. [https://bioconductor.org/packages/release/bioc/vignettes/ChAMP/inst/doc/ChAMP.html

Fortin JP, Triche TJ Jr., Hansen KD. Preprocessing, normalization and integration of the illumina humanmethylationepic array with Minfi. Bioinformatics. 2017;33:558–60.

Article  CAS  PubMed  Google Scholar 

Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S. A beta-mixture quantile normalization method for correcting probe design bias in illumina infinium 450 K DNA methylation data. Bioinformatics. 2013;29:189–96.

Article  CAS